Pelvic exenteration for locally advanced and recurrent prostate cancer.
Eur J Surg Oncol
; 50(7): 108384, 2024 Jul.
Article
de En
| MEDLINE
| ID: mdl-38749360
ABSTRACT
Locally advanced or recurrent prostate cancer which invades adjacent pelvic organs, bone or other soft tissue structures is a rare situation. This study aimed to report the outcomes of ten consecutive patients who underwent total pelvic exenteration for prostate cancer at a high-volume specialist centre. Two patients had locally advanced primary tumours, while eight had locally recurrent prostate cancer. Median operating time, blood loss, ICU stay, and hospital stay was 12.2 h (range 9.6-13.8), 2500 ml (500-3000), 4.5 days (2-7) and 36 days (21-78), respectively. There was no inpatient, 30-day, or 90-day mortality. Six patients developed a Clavien-Dindo III complication. R0 resection was achieved in eight patients. Median follow up was 16 months (range 2-77). At last follow up, five patients were alive without disease. These findings suggest that pelvic exenteration for locally advanced and recurrent prostate cancer is safe and represents a potentially curative treatment option for highly selected patients.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Exentération pelvienne
/
Tumeurs de la prostate
/
Récidive tumorale locale
Limites:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
Eur J Surg Oncol
/
Eur. j. surg. oncol
/
European journal of surgical oncology
Sujet du journal:
NEOPLASIAS
Année:
2024
Type de document:
Article
Pays de publication:
Royaume-Uni